Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Teva Pharma prices $15...

    Teva Pharma prices $15 bln in notes to fund Allergan generics deal

    Written by savita thakur thakur Published On 2016-07-20T14:16:09+05:30  |  Updated On 20 July 2016 2:16 PM IST
    Teva Pharma prices $15 bln in notes to fund Allergan generics deal

    Telaviv : Teva Pharmaceutical Industries Ltd said it successfully priced a debt offering for $15 billion worth of senior notes to help fund its acquisition of Allergan Plc's generic drug business.


    The fixed-rate notes mature between 2018 and 2046.


    Additional senior, unsecured benchmark-sized offerings of euro and/or Swiss franc-denominated multi-tranche debt securities are contemplated, subject to market conditions.


    Israel-based Teva has previously said it planned to sell $22 billion of bonds.


    "The strength of the demand, which was multiple times the size of the offering, and the attractive prices, are a testament to Teva's financial strength and strong reputation with investors," said Eyal Desheh, Teva's chief financial officer.


    The net proceeds from this offering will be about $14.9 billion, which Teva intends to use towards the cash portion of the $40.5 billion purchase of Allergan's generics business.


    Closing of the offering is expected on July 21.


    Barclays, Bank of America Merrill Lynch, BNP Paribas, Credit Suisse, HSBC, Mizuho Securities, Citigroup, Morgan Stanley, RBC Capital Markets and SMBC Nikko are acting as the joint book running managers for the offering. Rothschild & Co acted as sole financial advisor to Teva in connection with the offering.

    Allergan PlcBank of America Merrill LynchBNP ParibasCredit SuisseEyal Deshehgeneric drugHSBCMizuho SecuritiesMorgan StanleyRBC Capital MarketsSMBC NikkoTeva
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok